# A Study of LY3007113 in Participants With Advanced Cancer

> **NCT01463631** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 27 (actual)

## Conditions studied

- Metastatic Cancer

## Interventions

- **DRUG:** LY3007113

## Key facts

- **NCT ID:** NCT01463631
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2018-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01463631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01463631, "A Study of LY3007113 in Participants With Advanced Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01463631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*